Greg Chittick
BioCryst Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Virus-based gene therapy research, Cytomegalovirus and herpesvirus research, HIV/AIDS Research and Interventions, HIV Research and Treatment, HIV/AIDS drug development and treatment
Most-Cited Works
- → A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation(2018)210 cited
- → Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox(2017)128 cited
- → Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial(2020)45 cited
- → Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients (pts) with Brincidofovir: Final 36 Week Results from the Advise Trial(2017)15 cited
- → Long-term Safety and Efficacy Results of Once-Daily Emtricitabine-Based Highly Active Antiretroviral Therapy Regimens in Human Immunodeficiency Virus-Infected Pediatric Subjects(2008)14 cited
- → Preliminary Results from the AdVise Study Evaluating Brincidofovir (CMX001, BCV) for the Treatment of Disseminated and High-Risk Adenovirus (AdV) Infection(2015)9 cited
- → Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (HCT) Patients (pts) with Brincidofovir: 24 Week Interim Results from the AdVise Trial(2016)3 cited
- → Brincidofovir Decreases Adenovirus Viral Burden, Which is Associated with Improved Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients(2018)3 cited
- → Brincidofovir (BCV) for the Treatment of Adenovirus (AdV) Infection in Patients Receiving Liver Transplantation (LT)(2015)3 cited
- → LB-3Preliminary Safety Results and Antiviral Activity from the Open-label Pilot Portion of a Phase 3 Study to Evaluate Brincidofovir (BCV) for the Treatment of Adenovirus (AdV) Infection(2014)2 cited